Board of Directors
Providing a strategic vision for the future.
Douglas M. Fambrough, III Ph.D.
Chief Executive Officer
Douglas M. Fambrough, III Ph.D. co-founded Dicerna in 2007 and has served as the Company’s chief executive officer since 2010. Prior to joining Dicerna as CEO, Doug specialized in financing innovative life science technology companies as a general partner with Oxford Bioscience Partners, a Boston-based venture capital firm.
In 2003, Doug and two other investors founded Sirna Therapeutics, a first-generation RNA interference (RNAi) pioneer; he served on Sirna’s Board of Directors until the company was acquired by Merck for $1.1 billion in 2006. Other investments include Solexa, developer of the dominant ultra-high-throughput DNA sequencing platform, acquired by Illumina for $600 million; and Cambrios Technologies, which invented and now markets biologically inspired electronic materials for touch screens and flat panel displays. Before joining Oxford, Doug was a genomic scientist at the Whitehead/MIT Center for Genome Research (now known as the Broad Institute).
Doug graduated from Cornell University and obtained his Ph.D. in genetics at the University of California, Berkeley.
J. Kevin Buchi
Most recently, Mr. Kevin Buchi served as president and chief executive officer of TetraLogic Pharmaceuticals. Before TetraLogic, he served as corporate vice president of Global Branded Products at Teva Pharmaceutical Industries Limited from 2011 to May 2012.
Mr. Buchi was chief executive officer of Cephalon, Inc., which was acquired by Teva in October 2011. Mr. Buchi joined Cephalon in 1991 and, during his tenure, held various leadership positions, including chief financial officer and chief operating officer, before becoming Cephalon’s chief executive officer in December 2010. In addition, Mr. Buchi currently serves as a director of Amneal Pharmaceuticals Inc. and Benitec Biopharma Ltd. Mr. Buchi has previously served on the boards of several pharmaceutical companies, including EPIRUS Biopharmaceuticals, Inc., Alexza Pharmaceuticals, Inc. and Forward Pharma A/S.
Martin Freed, M.D.
Martin Freed, M.D., has been a member of the Dicerna board of directors since 2016. Dr. Freed has served as an independent consultant to several private pharmaceutical, biotechnology, and healthcare companies, specializing in clinical and general pharmaceutical development and clinical and regulatory strategy since February 2015.
He co-founded and served as chief medical officer of Civitas Therapeutics, Inc., from December 2010 to October 2014 (acquired by Acorda Therapeutics, Inc., or Acorda) and as senior vice president, clinical development of Acorda from October 2014 through January 2015.
In addition, Dr. Freed has served as chief medical officer and has provided strategic and operational planning and execution, as well as medical leadership for clinical pharmacology and development strategy and preclinical development for multiple pharmaceutical companies throughout his career. These companies include Avila Therapeutics, Inc., Taligen Therapeutics, Adnexus Therapeutics, Inc.,(acquired by Bristol-Myers Squibb), and Vitae Pharmaceuticals, Inc.
Dr. Freed spent nearly 14 years at GlaxoSmithKline and its predecessor, SmithKline Beecham Pharmaceuticals or SmithKline Beecham, where he served numerous roles including vice president, clinical development and medical affairs in the metabolism therapeutic area. He has authored over 100 publications or presentations.
Dr. Freed has been Board Certified in Internal Medicine, Nephrology and Clinical Pharmacology. He performed his internal medicine residency at Temple University Hospital and nephrology fellowship at Yale-New Haven Hospital. A Fellow of the American College of Physicians, Dr. Freed received his B.S. with Distinction in Biology from the University of Delaware and M.D. from Pennsylvania State University’s College of Medicine.
Brian Halak, Ph.D.
Partner, Domain Associates
Brian Halak, Ph.D. joined Domain in 2001 and became a partner in 2006. From 2000 to 2001, he was an associate with Advanced Technology Ventures, where he participated in the firm’s investments in Plexxikon, Percardia and Emphasys. Previously, Brian was a consultant at the Wilkerson Group, where he developed strategy for pharmaceutical and medical device companies.
Brian is currently a member of the Investment Advisory Council for Ben Franklin Technology Partners and BioAdvance, both of which are seed-stage investment groups in Philadelphia.
Brian holds a Ph.D. in immunology from Thomas Jefferson University and a B.S. in engineering from the University of Pennsylvania.
Stephen Hoffman, M.D., Ph.D.
Chief Executive Officer, Aerpio Pharmaceuticals
Stephen Hoffman, M.D., Ph.D. has served as a member of our board of directors since November 2007. Dr. Hoffman has been a senior advisor to PDL BioPharma, Inc. since February 2014. Prior to that, he served as a managing director at Skyline Ventures, a venture capital firm, from May 2007 until February 2014.
From January 2003 to March 2007, Dr. Hoffman was a general partner at TVM Capital, a venture capital firm. From 1994 to 2002, he served as president, chief executive officer and a member of the board of directors of Allos Therapeutics, Inc., a biopharmaceutical company, where he remained as chairman of the board until it was acquired by Spectrum Pharmaceuticals, Inc. in September 2012. From 1990 to 1994, Dr. Hoffman completed a fellowship in clinical oncology and a residency/fellowship in dermatology, both at the University of Colorado. Dr. Hoffman was the scientific founder of Somatogen Inc., a biotechnology company that was acquired by Baxter International, Inc. in 1998, where he held the position of vice president of science and technology from 1987 until 1990.
Dr. Hoffman currently serves on the board of directors of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Aerpio Pharmaceuticals, Inc. (OTC US: ARPO), where he is also chief executive officer, Bicycle Therapeutics Ltd, and Palleon Pharmaceuticals Inc. Previously, Dr. Hoffman also served on the boards of directors of Genocea Biosciences, Inc. (NASDAQ: GNCA), which he resigned from effective April 11, 2017, and Sirtris Pharmaceuticals, Inc., a pharmaceutical company that was acquired by GlaxoSmithKline (NYSE: GSK) in 2008.
Dr. Hoffman holds a Ph.D. in bio-organic chemistry from Northwestern University and an M.D. from the University of Colorado School of Medicine.
Peter Kolchinsky, Ph.D.
Partner, RA Capital
Peter Kolchinsky, Ph.D. is a co-founder and general partner of RA Capital Management, which has been investing in healthcare companies since 2002. He has served as a member of the National Academies Board on Global Science and Technology, authored an e-book titled, “The Entrepreneur’s Guide to a Biotech Startup,” and serves as an advisor to startup companies and non-profits.
Peter received his undergraduate degree in biology from Cornell University and a Ph.D. in virology from Harvard University, where he conducted research at Dana-Farber Cancer Institute on the entry mechanism of the human immunodeficiency virus (HIV).
Adam Koppel, M.D., Ph.D.
Managing Director, Bain Capital
Adam M. Koppel, M.D., Ph.D., has been a member of the Dicerna board of directors since April 2017. Dr. Koppel rejoined Bain Capital in 2016 as Managing Director of the Bain Capital Life Sciences Fund. He had initially joined Bain Capital Public Equity in 2003 where he was a leader within the healthcare sector until mid-2014.
During the period mid-2014 to mid-2016, Dr. Koppel was at Biogen where he served as EVP of Corporate Development and Chief Strategy Officer. Other than Dicerna, he sits on the board of directors of Solid Biosciences, PTC Therapeutics (NASD: PTCT) and Trevena (NASD: TRVN).
Prior to initially joining Bain Capital in 2003, Dr. Koppel was an Associate Principal at McKinsey & Co in New Jersey where he served a variety of healthcare companies.
Dr. Koppel received an M.D. and Ph.D. in Neuroscience from the University of Pennsylvania School of Medicine. He also received an MBA from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He graduated magna cum laude from Harvard University with a AB and AM in History and Science.
Dennis Langer, M.D., J.D.
Director, Dicerna Pharmaceuticals
Dennis H. Langer, M.D., J.D. has served as a member of our board of directors since November 2007. Dr. Langer previously served as the chairman of the board of directors and chief executive officer of AdvanDx, Inc., from January 2013 to August 2014.
Dr. Langer has been a clinical professor in the department of psychiatry at Georgetown University School of Medicine since September 2003. From August 2005 to May 2010, Dr. Langer served as managing partner of Phoenix IP Ventures, LLC. From January 2004 to July 2005, he served as president, North America of Dr. Reddy’s Laboratories, Inc. (NYSE: RDY). From September 1994 until January 2004, Dr. Langer held several positions at GlaxoSmithKline plc (NYSE: GSK) and its predecessor, SmithKline Beecham, culminating with senior vice president of research and development. Dr. Langer currently serves on the board of directors of Myriad Genetics, Inc. (NASDAQ: MYGN), Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) and Alzheon, Inc. Dr. Langer previously served on the boards of directors of Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), Cytogen Corporation (NASDAQ:CYTO), Delcath Systems, Inc. (NASDAQ: DCTH), Myrexis, Inc. (NASDAQ:MYRX), Pharmacopeia, Inc. (NASDAQ:PCOP), and Sirna Therapeutics, Inc. (NASDAQ:RNAI).
Dr. Langer received a J.D. from Harvard Law School, an M.D. from Georgetown University School of Medicine and a B.A. in biology from Columbia University.
David M. Madden
Chairman of the Board of Directors Dicerna Pharmaceuticals Founder and Principal, Narrow River Management
David Madden has been chairman of the board of directors of Dicerna Pharmaceuticals since 2009. He is a founder and principal with Narrow River Management, LP, an investment management company with a focus on equity investments in the emerging pharmaceutical industry.
From 2000 to 2003, David was co-CEO of Royalty Pharma AG, a private investment management firm specializing in the acquisition of royalty interests in pharmaceutical products. Prior to that position, he was a managing member of Pharmaceutical Partners, LLC, and was president, CEO and a director of Selectide Corporation, a development-stage pharmaceutical company, which was acquired by Marion Merrill Dow in 1995. Additionally, David serves as chairman of the board of Adolor Corporation, and is a member of the board of directors of the Hospital for Special Surgery in New York City.
David holds a B.S. in electrical engineering from Union College and an M.B.A. from Columbia University.
Cynthia Smith has more than 20 years of broad leadership experience within the healthcare industry. Most recently she has served as chief commercial officer and a member of the executive team of ZS Pharma, acquired by AstraZeneca, where she led efforts to transition the company from the development stage to a commercial enterprise.
Prior to joining ZS Pharma, Ms. Smith served as vice president, market access and commercial development at Affymax, Inc. Earlier, she held various senior leadership positions in market access, corporate strategy, government relations, and external affairs at Merck & Co. Before beginning her career in the biopharmaceutical industry, Ms. Smith served as a healthcare policy analyst in the White House Office of Management and Budget. She previously served on the board of Nivalis Therapeutics.